Studies highlight the dual role of TMAO in the pathogenesis of cardiovascular diseases

In their latest publication researchers at the Laboratory of Pharmaceutical Pharmacology (LIOS) have demonstrated that microbiota-derived metabolite trimethylamine N-oxide (TMAO) protects mitochondrial energy metabolism and cardiac functionality in a rat model of right ventricle heart failure. These results provide a novel insight into the theory, that the role of TMAO in the pathogenesis of cardiometabolic diseases is not limited to either detrimental or protective effects, suggesting that it might actually be dual and depend on specific conditions. The research has been published in the journal “Frontiers in Cell and Developmental Biology” (IF = 5.201, 2019).

Videja, M.; Vilskersts, R.; Korzh, S.; Cirule, H.; Sevostjanovs, E.; Dambrova, M.; Makrecka-Kuka, M.
Microbiota-Derived Metabolite Trimethylamine N-Oxide Protects Mitochondrial Energy Metabolism and Cardiac Functionality in a Rat Model of Right Ventricle Heart Failure.
Front. Cell Dev. Biol., 2021. DOI: 10.3389/fcell.2020.622741

This study was funded by the Latvian Council of Science project “Trimethylamine-N-oxide as a link between an unhealthy diet and cardiometabolic risks” No. Izp-2018/1-0081.